High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed — Stella

Home/Retinoblastoma/

View on ClinicalTrials.gov

Recruiting

Back to Retinoblastoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Fudan Eye & ENT Hospital, Shanghai, China

Key details

Phase

Very early testing

Sponsor

Eye & ENT Hospital of Fudan University

Enrollment target

~10 participants

Started

April 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

1 Year – 12 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.